QQQ   444.26 (-0.13%)
AAPL   171.11 (-1.27%)
MSFT   419.80 (-0.39%)
META   485.91 (-1.61%)
GOOGL   150.67 (-0.13%)
AMZN   180.18 (+0.19%)
TSLA   177.58 (-1.25%)
NVDA   906.85 (+0.48%)
NIO   4.57 (-2.14%)
AMD   181.77 (+1.21%)
BABA   72.47 (+1.23%)
T   17.63 (+0.46%)
F   13.19 (+1.00%)
MU   118.04 (-0.92%)
CGC   9.87 (+3.35%)
GE   175.31 (-2.67%)
DIS   122.62 (+1.36%)
AMC   3.69 (-14.98%)
PFE   28.02 (+0.86%)
PYPL   67.34 (+1.16%)
XOM   115.69 (+0.63%)
QQQ   444.26 (-0.13%)
AAPL   171.11 (-1.27%)
MSFT   419.80 (-0.39%)
META   485.91 (-1.61%)
GOOGL   150.67 (-0.13%)
AMZN   180.18 (+0.19%)
TSLA   177.58 (-1.25%)
NVDA   906.85 (+0.48%)
NIO   4.57 (-2.14%)
AMD   181.77 (+1.21%)
BABA   72.47 (+1.23%)
T   17.63 (+0.46%)
F   13.19 (+1.00%)
MU   118.04 (-0.92%)
CGC   9.87 (+3.35%)
GE   175.31 (-2.67%)
DIS   122.62 (+1.36%)
AMC   3.69 (-14.98%)
PFE   28.02 (+0.86%)
PYPL   67.34 (+1.16%)
XOM   115.69 (+0.63%)
QQQ   444.26 (-0.13%)
AAPL   171.11 (-1.27%)
MSFT   419.80 (-0.39%)
META   485.91 (-1.61%)
GOOGL   150.67 (-0.13%)
AMZN   180.18 (+0.19%)
TSLA   177.58 (-1.25%)
NVDA   906.85 (+0.48%)
NIO   4.57 (-2.14%)
AMD   181.77 (+1.21%)
BABA   72.47 (+1.23%)
T   17.63 (+0.46%)
F   13.19 (+1.00%)
MU   118.04 (-0.92%)
CGC   9.87 (+3.35%)
GE   175.31 (-2.67%)
DIS   122.62 (+1.36%)
AMC   3.69 (-14.98%)
PFE   28.02 (+0.86%)
PYPL   67.34 (+1.16%)
XOM   115.69 (+0.63%)
QQQ   444.26 (-0.13%)
AAPL   171.11 (-1.27%)
MSFT   419.80 (-0.39%)
META   485.91 (-1.61%)
GOOGL   150.67 (-0.13%)
AMZN   180.18 (+0.19%)
TSLA   177.58 (-1.25%)
NVDA   906.85 (+0.48%)
NIO   4.57 (-2.14%)
AMD   181.77 (+1.21%)
BABA   72.47 (+1.23%)
T   17.63 (+0.46%)
F   13.19 (+1.00%)
MU   118.04 (-0.92%)
CGC   9.87 (+3.35%)
GE   175.31 (-2.67%)
DIS   122.62 (+1.36%)
AMC   3.69 (-14.98%)
PFE   28.02 (+0.86%)
PYPL   67.34 (+1.16%)
XOM   115.69 (+0.63%)
NASDAQ:ACHL

Achilles Therapeutics (ACHL) Stock Price, News & Analysis

$1.24
+0.05 (+4.20%)
(As of 12:52 PM ET)
Today's Range
$1.19
$1.29
50-Day Range
$0.82
$1.57
52-Week Range
$0.74
$1.76
Volume
152,162 shs
Average Volume
757,067 shs
Market Capitalization
$50.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

Achilles Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
812.9% Upside
$11.00 Price Target
Short Interest
Healthy
0.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.32mentions of Achilles Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.52) to ($1.36) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.23 out of 5 stars

Medical Sector

561st out of 939 stocks

Biological Products, Except Diagnostic Industry

92nd out of 155 stocks

ACHL stock logo

About Achilles Therapeutics Stock (NASDAQ:ACHL)

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

ACHL Stock Price History

ACHL Stock News Headlines

Achilles Therapeutics plc (NASDAQ:ACHL) Short Interest Update
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Achilles Therapeutics PLC ADR
Achilles Therapeutics PLC ADR (ACHL)
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
ACHL Achilles Therapeutics plc
Achilles Therapeutics GAAP EPS of -$0.44
See More Headlines
Receive ACHL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achilles Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/04/2023
Today
3/28/2024
Next Earnings (Estimated)
4/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ACHL
Fax
N/A
Employees
234
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.00
High Stock Price Target
$11.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+809.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-71,180,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.03 per share

Miscellaneous

Free Float
38,589,000
Market Cap
$49.34 million
Optionable
Not Optionable
Beta
1.10
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Iraj Ali Ph.D. (Age 49)
    CEO & Director
  • Dr. Karl Stuart Peggs M.D. (Age 57)
    Founder & Chief Medical Officer
  • Dr. Mark William Lowdell BSc (Age 61)
    FRCPath, MICR, MSc, Ph.D., Founder
  • Dr. Charles Swanton FMEDSCI (Age 51)
    M.D., Ph.D., Founder
  • Dr. Sergio A. Quezada Ph.D. (Age 48)
    Founder & Chief Scientific Officer
  • Mr. Robert Coutts (Age 40)
    Chief Financial Officer
  • Mr. Lee M. Stern
    Vice President of Investor Relations & External Communications
  • Mr. Daniel Carey Cazel Hood
    General Counsel & Company Secretary
  • Julia Wilson
    Head of Communications
  • Mr. Tariq Ahmed
    Executive Vice President of People

ACHL Stock Analysis - Frequently Asked Questions

Should I buy or sell Achilles Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Achilles Therapeutics in the last twelve months. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ACHL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACHL, but not buy additional shares or sell existing shares.
View ACHL analyst ratings
or view top-rated stocks.

What is Achilles Therapeutics' stock price target for 2024?

2 equities research analysts have issued 12 month price targets for Achilles Therapeutics' stock. Their ACHL share price targets range from $11.00 to $11.00. On average, they anticipate the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 812.9% from the stock's current price.
View analysts price targets for ACHL
or view top-rated stocks among Wall Street analysts.

How have ACHL shares performed in 2024?

Achilles Therapeutics' stock was trading at $0.8890 at the start of the year. Since then, ACHL stock has increased by 35.5% and is now trading at $1.2050.
View the best growth stocks for 2024 here
.

Are investors shorting Achilles Therapeutics?

Achilles Therapeutics saw a decline in short interest in March. As of March 15th, there was short interest totaling 68,900 shares, a decline of 55.2% from the February 29th total of 153,700 shares. Based on an average trading volume of 723,600 shares, the short-interest ratio is currently 0.1 days. Currently, 0.2% of the company's shares are sold short.
View Achilles Therapeutics' Short Interest
.

When is Achilles Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 2nd 2024.
View our ACHL earnings forecast
.

How were Achilles Therapeutics' earnings last quarter?

Achilles Therapeutics plc (NASDAQ:ACHL) issued its quarterly earnings results on Friday, August, 4th. The company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by $0.02.

When did Achilles Therapeutics IPO?

Achilles Therapeutics (ACHL) raised $176 million in an initial public offering on Wednesday, March 31st 2021. The company issued 9,800,000 shares at $17.00-$19.00 per share. JPMorgan, BofA Securities, Piper Sandler, Chardan, Oppenheimer & Co. and Kempen & Co. served as the underwriters for the IPO.

Who are Achilles Therapeutics' major shareholders?

Achilles Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Fcpm Iii Services B.V. (5.86%), Citadel Advisors LLC (0.27%), Vestal Point Capital LP (0.27%) and Virtu Financial LLC (0.10%).

How do I buy shares of Achilles Therapeutics?

Shares of ACHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACHL) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners